News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,158 Results
Type
Article (38964)
Company Profile (276)
Press Release (643918)
Section
Business (203819)
Career Advice (1985)
Deals (35357)
Drug Delivery (84)
Drug Development (80768)
Employer Resources (168)
FDA (16085)
Job Trends (14796)
News (344460)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1215)
Approvals (16003)
Artificial intelligence (114)
Bankruptcy (352)
Best Places to Work (11463)
Biotechnology (196)
Breast cancer (105)
Cancer (896)
Cardiovascular disease (79)
Career advice (1656)
Cell therapy (195)
Clinical research (63908)
Collaboration (322)
Compensation (167)
COVID-19 (2522)
Cystic fibrosis (78)
Data (847)
Diabetes (132)
Diagnostics (6093)
Earnings (84130)
Employer resources (146)
Events (108814)
Executive appointments (241)
FDA (16525)
Funding (287)
Gene therapy (147)
GLP-1 (556)
Government (4316)
Healthcare (18652)
Infectious disease (2595)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16268)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (154)
Manufacturing (149)
Medical device (13144)
Medtech (13149)
Mergers & acquisitions (19103)
Metabolic disorders (356)
Neuroscience (1453)
NextGen Class of 2024 (6494)
Non-profit (4462)
Northern California (1196)
Obesity (212)
Opinion (176)
Patents (94)
People (56113)
Phase I (19819)
Phase II (28138)
Phase III (21011)
Pipeline (206)
Postmarket research (2553)
Preclinical (8425)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21433)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1074)
Startups (3560)
United States (11552)
Vaccines (535)
Weight loss (156)
Date
Today (163)
Last 7 days (801)
Last 30 days (2766)
Last 365 days (35696)
2024 (30263)
2023 (40074)
2022 (51173)
2021 (55713)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (37005)
Australia (6034)
California (2709)
Canada (1168)
China (208)
Colorado (117)
Connecticut (120)
Europe (79211)
Florida (392)
Georgia (98)
Illinois (306)
Indiana (176)
Kansas (95)
Maryland (513)
Massachusetts (2191)
Michigan (142)
Minnesota (247)
New Jersey (818)
New York (828)
North Carolina (659)
Northern California (1196)
Ohio (125)
Pennsylvania (742)
South America (1091)
Southern California (1074)
Texas (379)
Utah (79)
Washington State (321)
683,158 Results for "aditxt inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
October 31, 2024
·
4 min read
Deals
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
Aditxt, Inc. announced that it has entered into a definitive arrangement agreement to acquire Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures.
April 2, 2024
·
13 min read
Press Releases
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
September 20, 2024
·
9 min read
Press Releases
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
October 10, 2024
·
8 min read
Deals
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc.
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc.
December 12, 2023
·
13 min read
Press Releases
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
October 3, 2024
·
9 min read
Press Releases
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
October 28, 2024
·
5 min read
News
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
October 21, 2024
·
6 min read
Press Releases
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
September 24, 2024
·
6 min read
BioCapital
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
Aditxt, Inc. announced that it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550, subject to a mandatory panel monitor until December 29, 2024.
January 2, 2024
·
3 min read
1 of 68,316
Next
